328 related articles for article (PubMed ID: 10383160)
1. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.
Horiguchi S; Petersson M; Nakazawa T; Kanda M; Zea AH; Ochoa AC; Kiessling R
Cancer Res; 1999 Jun; 59(12):2950-6. PubMed ID: 10383160
[TBL] [Abstract][Full Text] [Related]
2. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.
Kono K; Salazar-Onfray F; Petersson M; Hansson J; Masucci G; Wasserman K; Nakazawa T; Anderson P; Kiessling R
Eur J Immunol; 1996 Jun; 26(6):1308-13. PubMed ID: 8647210
[TBL] [Abstract][Full Text] [Related]
3. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
4. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
Seo N; Tokura Y; Takigawa M; Egawa K
J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
Liu Y; Bi X; Xu S; Xiang J
Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
[TBL] [Abstract][Full Text] [Related]
6. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
7. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
9. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
10. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.
Roberts MR; Cooke KS; Tran AC; Smith KA; Lin WY; Wang M; Dull TJ; Farson D; Zsebo KM; Finer MH
J Immunol; 1998 Jul; 161(1):375-84. PubMed ID: 9647246
[TBL] [Abstract][Full Text] [Related]
11. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z
Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292
[TBL] [Abstract][Full Text] [Related]
12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
13. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
15. Modulation of immune response following dietary genistein exposure in F0 and F1 generations of C57BL/6 mice: evidence of thymic regulation.
Guo TL; Chi RP; Zhang XL; Musgrove DL; Weis C; Germolec DR; White KL
Food Chem Toxicol; 2006 Mar; 44(3):316-25. PubMed ID: 16162389
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.
Driessens G; Gordower L; Nuttin L; Stordeur P; Blocklet D; Egrise D; Velu T; Bruyns C
Cancer Immunol Immunother; 2008 Dec; 57(12):1745-56. PubMed ID: 18369621
[TBL] [Abstract][Full Text] [Related]
17. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
18. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns.
Doherty DG; Norris S; Madrigal-Estebas L; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
J Immunol; 1999 Aug; 163(4):2314-21. PubMed ID: 10438977
[TBL] [Abstract][Full Text] [Related]
19. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease.
Frydecka I; Boćko D; Kosmaczewska A; Ciszak L; Morilla R
Br J Cancer; 2001 May; 84(10):1339-43. PubMed ID: 11355944
[TBL] [Abstract][Full Text] [Related]
20. Alterations in signal transducing molecule CD3 zeta in patients with neoplastic diseases.
Frydecka I; Kaczmarek P; Boćko D; Kosmaczewska A; Ciszak L
Arch Immunol Ther Exp (Warsz); 1998; 46(6):355-9. PubMed ID: 9883314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
